Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Necrotizing Soft Tissue Infections
Interventions
DRUG

AB103

AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion

DRUG

Placebo

Normal saline (0.9% sodium chloride) administered as a single IV infusion

Trial Locations (7)

15261

University of Pittsburgh Medical Center, Pittsburgh

21201

University of Maryland Medical Center, Baltimore

98104

Harborview Medical Center, Seattle

Unknown

University of Southern California Los Angeles, Los Angeles

San Francisco General Hospital, San Francisco

University of Florida, Gainesville

Oregon Health and Science University, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Atox Bio Ltd

INDUSTRY

NCT01417780 - Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients | Biotech Hunter | Biotech Hunter